Methylene Diphenyl Diisocyanate by DEBACKER Linda et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EUR 24244 EN  - 2010
European Union 
Summary Risk Assessment Report 
Existing Substances – 3rd Priority List 
CAS: 26447-40-5 EINECS No: 247-714-0 
 
Methylene Diphenyl Diisocyanate 
N 
C 
 O 
N 
C 
  O 
Our mission is to protect the interests and health of the consumer in the framework of EU 
legislation on chemicals, food and consumer products. We work in close partnership with other 
EC Directorate-Generals by providing scientific and technical support from scientific 
research/analysis in our areas of competence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
European Commission 
Joint Research Centre 
Institute for Health and Consumer Protection 
 
Contact information 
Address: Via E. Fermi 2749 - 21027 Ispra (VARESE) - Italy 
E-mail: jrc-ihcp-communication@ec.europa.eu 
Tel.: +39 0332 785959 
Fax: +39 0332 785730 
 
http://ihcp.jrc.ec.europa.eu/ 
http://www.jrc.ec.europa.eu/ 
http://ecb.jrc.ec.europa.eu/ 
 
Legal Notice 
Neither the European Commission nor any person acting on behalf of the Commission is 
responsible for the use which might be made of this publication. 
 
Europe Direct is a service to help you find answers 
to your questions about the European Union 
 
Freephone number (*): 
00 800 6 7 8 9 10 11 
 
(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. 
 
A great deal of additional information on the European Union is available on the Internet. 
It can be accessed through the Europa server http://europa.eu/ 
 
JRC56623   
 
EUR 24244 EN 
ISSN 1018-5593 
ISBN 978-92-79-14996-2
DOI 10.2788/60947 
 
Luxembourg: Office for Official Publications of the European Communities 
 
© European Communities, 2010 
 
Reproduction is authorised provided the source is acknowledged 
 
Printed in Italy 
 
 
 
 
 
METHYLENE DIPHENYL DIISOCYANATE 
(MDI) 
 
CAS No: 26447-40-5 
EINECS No: 247-714-0 
 
SUMMARY RISK ASSESSMENT REPORT 
 
 
 
Final report, 2005 
 
Belgium 
 
 
 
Rapporteur for the risk assessment of methylenediphenyl diisocyanate is Belgium 
Contact point: 
 
BE Rapporteur: 
Federal Public Service Health, Food-
Chain Safety and Environment 
Environment Directorate-general 
Mr. R. Moreau, General Director 
Risk Management 
Place Victor Horta, B 10 
1060  Brussels 
Contact point: 
Linda.debacker@health.fgov.be 
Karen.VanMalderen@health.fgov.be 
 
Scientific Expertise:  
Environmental part: 
University of Liège 
Laboratory of Animal 
Ecology and Ecotoxicology 
Quai Van Beneden 22 
B-4020 Liège 
Belgium 
Prof. J.P. Thomé 
C. Joaquim-Justo 
 
 
Human Health part: 
Katholieke Universiteit Leuven 
Laboratium voor Pneumologie 
Eenheid voor Longtoxicologie 
Herestraat 49 bus 706 
B-3000 Leuven 
België 
Prof. Dr. B. Nemery 
H..Vanhooren 
 Date of Last Literature Search: 2003 
Review of report by MS Technical Experts finalised: 2004 
Final report: 2005 
 
© European Communities, 2010 
 
  III
PREFACE 
This report provides a summary, with conclusions, of the risk assessment report of the 
substance methylenediphenyl diisocyanate (MDI) that has been prepared by the Belgian 
Competent Authorities in the context of Council Regulation (EEC) No. 793/93 on the 
evaluation and control of existing substances.  
For detailed information on the risk assessment principles and procedures followed, the 
underlying data and the literature references the reader is referred to the comprehensive Final 
Risk Assessment Report (Final RAR) that can be obtained from the JRC-IHCP website1. The 
Final RAR should be used for citation purposes rather than this present Summary Report. 
 
                                                 
1 Former - European Chemicals Bureau – Existing Chemicals – http://ecb.jrc.ec.europa.eu/ 
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1 GENERAL SUBSTANCE INFORMATION 
1.1 IDENTIFICATION OF THE SUBSTANCE 
CAS Number:  26447-40-5 
EINECS Number: 247-714-0 
IUPAC name:  Methylenebis (phenyl isocyanate) (SIDS, 1994)  
   Methylenediphenyl diisocyanate 
Synonyms:  MDI (common name) 
   4,4’-diphenyl methane diisocyanate 
 2,4’-diphenyl methane diisocyanate 
 2,2’-diisocyanatodiphenylmethane 
 Methylene bisphenyl isocyanate 
 Crude MDI 
 Polymeric MDI 
 PMDI 
 Generic MDI 
   Non isomer specific MDI 
Molecular formula: C15H10N2O2 (monomeric) 
   C15H10N2O2 . [C8H5NO ]n (polymeric) 
 
Structural formula: 4,4’-MDI     Polymeric MDI 
                                  
 
 
Molecular weight: 
Monomeric MDI: 250.26 
 
 
 
Polymeric MDI: 290-400 
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1.2 PURITY/IMPURITIES, ADDITIVES 
Composition of the substance 
4,4’-MDI: 4,4’-MDI > 97% 
                        2,4’-MDI  1.5-2.5% 
 2,2’-MDI > 0.5% 
 
 
Polymeric MDI: 4,4’-MDI 40-50% 
 2,4’-MDI 2.5-4.0% 
 2,2’-MDI 0.1-0.2% 
           Homologues 60-50% 
 
 
Impurities  
monochlorobenzene (max. 80 ppm) 
phenylisocyanate (max. 50ppm) 
hydrogen chloride 
Additives (concentration range 200 - 1000ppm):  
triphenyl phosphite (TPP) - dinonyl phthalate (DNP) - triethyl phosphate (TEP) – 
butyl hydroxy toluene (BHT) 
1.3 PHYSICO-CHEMICAL PROPERTIES 
Table 1.1    Summary of physico-chemical properties 
Property Value ( 4.4 MDI ) Value ( Polymeric MDI) 
Physical state (at ntp):  solid (at ntp)  liquid 
 
Melting point 39-43°C 
 
 5°C 
Boiling point (at 101100 Pa): > 300°C 
 
 
Relative density (20°C):  1.325 
 
(20°)  1.2381 
 
Vapour pressure (20°C): <0.002 Pa (20°C) < 0.005 Pa 
Water solubility 0.02 mg/l (calculated, MDI reacts with water) 
 
 
Partition coefficient 
n-octanol/water (log value) 
4.5  
Granulometry 80% on 1.25 mm 
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1.4 CLASSIFICATION 
 
Environment 
No classification or labelling for the environment.  
Human Health 
Classification: 
Classification according to Annex I of the Directive 67/548/EEC (25th ATP, i.e. Dir. 
98/98/EC, O.J. 30.12.98):  
One entry (Index n° 615-005-00-9) in the Annex I applies to free diphenylmethane 
diisocyanate isomers:  
Xn; R20 Xi; R36/37/38 R42/43  
 
Labelling:   
Symbol: St Andrew’s Cross Xn  
R: 20-36/37/38-42/43  
S: (1/2-)23-36/37-45  
The following concentration limits are applicable and the label must indicate the presence 
of the substance: 
C ≥ 25 %    Xn: R20-36/37/38-42/43 
5 % ≤ C < 25 %   Xn: R36/37/38-42/43 
1 % ≤ C < 5 %   Xn: R42/43 
0,1 % ≤ C < 1 %   Xn; R42 
Note 2 of Annex I (Dir. 67/548/EEC) mentions: The concentration of isocyanate stated is 
the percentage by weight of the free monomer calculated with reference to the total 
weight of the preparation.  
Note C: Some organic substances may be marketed either in a specific isomeric form or 
as a mixture of several isomers.  
On the label must be stated whether the substance is a specific isomer or a mixture of 
isomers.  
Following the 30th ATP 67/548, a new classification and labelling is proposed: 
Classification:  
Carc. Cat. 3; R40 Xn; R20-48/20 Xi; R36/37/38 R42/43 
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Labelling:  
Symbol: St Andrew’s Cross Xn  
R: 20 - 36/37/38 – 40 - 42/43 - 48/20   
S: (1/2)-23-36/37-45  
C ≥ 25 %    Xn; R20-36/37/38-40-42/43-48/20 
10 % ≤ C < 25 %   Xn; R36/37/38-40-42/43-48/20 
5 % ≤ C < 10 %   Xn; R36/37/38-40-42/43 
1 % ≤ C < 5 %   Xn; R40-42/43 
0,1 % ≤ C < 1 %   Xn; R42 
 
Note 2 of Annex I (Dir. 67/548/EEC) mentions: The concentration of isocyanate stated is 
the percentage by weight of the free monomer calculated with reference to the total 
weight of the preparation.  
Note C: Some organic substances may be marketed either in a specific isomeric form or 
as a mixture of several isomers.  
On the label must be stated whether the substance is a specific isomer or a mixture of 
isomers.  
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2 GENERAL INFORMATION ON EXPOSURE 
Production  
The life span of MDI and the corresponding tonnage are represented in the following figure: 
 
Production of MDI and further processing to prepolymers take place in closed systems and 
are carried out in a rather small number of industrial sites (11 sites for total production in EU).  
Some prepolymers will contain unreacted MDI in a proportion that will vary according to 
their intended use. Since no data could be found concerning the accurate proportion of MDI in 
these products, the total volume of prepolymers produced was used when processing of 
prepolymers was considered. 
Some speciality MDI's (i.e. coatings, paintings, adhesives, sealants and cast elastomers) 
products may contain free MDI that will react immediately with air when used. Even if most 
of these products will be used in industrial structures, a certain amount will be sold to the 
public at large in do-it-yourself products. Consequently, the processing of prepolymers to 
speciality MDI’s was attributed to the main category V (wide dispersive use) as a worst case 
assumption. 
Polymer 
production 
(polyurethanes)
Production 
790 ktpa 
Exportation: 105 
Importation: 3.5 
Speciality MDI's (Wide 
dispersive use)
135ktp
510 ktpa 
Tonnage 
689 ktpa 
Prepolymer 
production 
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Categories considered in the risk assessment are as follow: 
 
Table 3.1    Life span stages, categories and volumes used for estimation of MDI releases 
Life span stage Industry category Use category Main category Volume (ktpa) 
Production 11 Polymers industry 43 Process regulators 
(dry monomers) 
Ic Isolate intermediates with 
controlled transport 
790 
Processing to PU 11 Polymers industry 43 Process regulators 
(dry monomers) 
III Non dispersive use 511 
Processing to prepolymers 11 Polymers industry 43 Process regulators 
(dry monomers) 
III Non dispersive use 179 
Processing of prepolymers 
– speciality MDI's 
11 Polymers industry 43 Process regulators 
(dry monomers) 
V Wide dispersive use  44 
Processing of prepolymers 
other than speciality MDI's 
11 Polymers industry 43 Process regulators 
(dry monomers) 
III Non dispersive use 135 
 
Uses 
MDI’s are sold to many downstream users (ca 3600 in EU). Main applications for MDI are: 
polyurethane foams (69%) e.g. in refrigerators, boilers, spray foams, roofing, automotive 
seating, carpet backing, office furniture,…; 
coatings, adhesives, sealants and elastomers (26%) e.g. in sport surfaces, windscreens, 
containers, aircraft, wheels, tyres, electrical joints,…; 
Other uses are thermoplastic polyurethanes (tubes, hoses, cable sheatings for electrical 
applications, sports shoes and ski boots) and polyurethane fibres. MDI is also used as grouting 
agent in rock consolidation or sealing of water leaks in tunnels or geotechnical construction 
works. 
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3 ENVIRONMENT 
3.1 ENVIRONMENTAL EXPOSURE 
Synthesis of MDI takes place in closed systems; since the NCO groups2 of MDI react readily 
with OH groups, contact of MDI with water is carefully avoided through production and 
storage stages. Consequently releases of MDI to effluents are expected to be virtually null at 
the production sites. Likewise releases to sediment and soil are also expected to be negligible. 
Indeed, although releases of MDI to atmosphere might occur during production, they are 
expected to be low. Moreover exhaust gazes produced during the MDI formation reaction are 
treated by incineration or scrubbing of MDI vapours. 
As far as transport and storage are concerned, waste water resulting from cleaning and 
decontamination of road tankers and tank containers is not considered to contain any MDI but 
rather polyurethanes and polyureas which are insoluble and inert compounds. 
The MDI produced is mainly directly processed for the synthesis of polyurethanes products in 
which all di-isocyanates are reacted. Emissions of MDI to soil, waste water and thus sediment 
linked to this processing stage are expected to be negligible and polyurethane products neither 
contain generic isocyanates nor biologically available isocyanate group. Since the reaction of 
MDI and OH groups is exothermic, it is possible that some MDI might evaporate near the exit 
of the device where MDI and polyols are mixed (mixing head). Nevertheless the proportion of 
MDI which indeed reaches the atmosphere is likely to be low because of the low vapour 
pressure of MDI and the further treatment of the vapours collected at this stage. 
Part of the MDI produced is processed in prepolymers that are mainly processed in big plants. 
Nevertheless, some applications of MDI concern small companies or may even be sold to the 
public at large in do-it-yourself products. So releases relevant for processing of these latter 
types of applications, which essentially concern coatings, adhesives, sealants and cast 
elastomers, are not well controlled or defined. This aspect was tackled by allocating 
prepolymer processing for such kind of products to the main category “wide dispersive use” 
as a worst case approach. 
A somewhat particular use of MDI is its utilisation as grouting agent in tunnels; a laboratory 
scaled study conducted in the frame of the Romeriksporten tunnel construction (Norway) 
where MDI has been used to reduce water leaks from the tunnel indicated that the levels of 
MDI and MDA released from the foam to surrounding water were negligible. 
PECs presented in table 3.2 and 3.3 were calculated with the European Union System for the 
Evaluation of Substances program (EUSES 1.00) on the basis of emission factors as included 
in release tables of TGD and on the basis of specific release information provided by industry 
when available. 
                                                 
2  Nitrogen, Carbon, Oxygen –group (added to the aromatic ring) 
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Table 3.2    Local PECs 
Environmental 
compartment 
Production Processing 
to PU 
Processing to 
prepolymers 
Processing of 
prepolymers 
speciality MDI's 
Processing of 
prepolymers other than 
speciality MDI's 
Air 
(mg/m3) 
8.14 10-7 2.35 10-5 7.71 10-6 5.25 10-6 1. 05 10-5 
Surface water 
(mg/l) 
1.37 10-6 1.37 10-6 1.37 10-6 1.37 10-6 1.37 10-6 
Agricultural soil 
(mg/kg wwt) 
5.38 10-5 4.85 10-4 1.85 10-4 1.38 10-4 2.38 10-4 
Grassland 
(mg/kg wwt) 
6.00 10-7 7.22 10-4 2.61 10-4 1.89 10-4 3.43 10-4 
Sediment 
(mg/kg wwt) 
1.66 10-4 1.66 10-4 1.66 10-4 1.66 10-4 1.66 10-4 
 
 
Table 3.3    Regional PECs 
Environmental compartment Regional PEC 
Surface water 1.38 10-6 mg/l 
Air 2.06 10-7 mg/m3 
Agricultural soil 4.21 10-5 mg/kg wwt 
Natural soil 4.23 10-5 mg/kg wwt 
Sediment 6.94 10–5 mg/kg wwt 
 
3.2 EFFECTS ASSESSMENT 
In all tests performed, MDI had to be either added to water or to some moistened material; 
considering the high reactivity of MDI with water, it is most probable that it was the 
breakdown products that were being tested and not MDI. The hydrolysis products of MDI and 
water are dependent on the conditions of the mixing of the MDI with water. Under conditions 
of low dispersion the immediate products are insoluble, solid and inert polyureas. Under 
conditions of high dispersion, some MDA as an initial hydrolysis product may be formed, 
however, given its extreme reactivity with MDI, MDA is rapidly transformed. 
Consequently, PNECs have been calculated on the basis of nominal concentrations even 
though the amount of MDI in test media was always most probably well below these values. 
Nominal values have been considered as representative of the amount of product that can be 
added per volume of media above which an effect will not occur. The reader should thus be 
forewarned that designation of the following effect thresholds by PNEC is not consistent with 
the approach adopted for non-reactive chemicals. 
Effect data are summarised in the following table. 
  CHAPTER 3. ENVIRONMENT 
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Table 3.4    Summarised effect data available 
Test organism 
 
Endpoint Value 
Fish Acute/short-term: EC50 from > 1000 to > 3000 mg/l 
Daphnid Acute/short-term: EC50 > 1000 mg/l 
 Reproduction/long-term: NOEC >10 mg/l 
Algae 72 hours: EC50 >1640 mg/l 
                NOEC >1640 mg/l 
Earthworm 14 days: EC50 > 1000 mg/kg 
Plant 14 days: EC50 > 1000 mg/kg 
E. coli 10 days inhibition growth: EC0 ≥ 100 mg/l 
Activated sludge Respiration inhibition test:EC50 > 100 mg/l 
 
Since all tests performed were limit tests, no concentration-effect relationship could be 
established. Consequently NOECs were not considered for calculating the PNEC as advised 
in the TGD. 
PNECwater was calculated as : > 1000 mg.l-1/1000 = > 1 mg/l; 
PNECsoil as: > 1000 mg.kg -1/1000 = > 1 mg/kg and, 
PNECmicro as: >100 mg/l/100: > 1 mg/l. 
PNECsediment was estimated by the equilibrium partitioning approach and resulted in a value 
of 108 mg/kg W.W. 
3.3 RISK CHARACTERISATION 
As shown in table 3.5, all PEC/PNEC ratios calculated are below 1 (conclusion ii). 
Table 3.5:    Calculated PEC/PNEC ratios 
Compartment Production Processing 
to PU 
Processing to 
prepolymers 
Processing of 
prepolymers 
speciality MDI's 
Processing of 
prepolymers other 
than  
speciality MDI's 
Regional 
Water <1.37 10-6 <1.37 10-6 <1.37 10-6 <1.37 10-6 <1.37 10-6 <1.37 10-6 
Soil <5.36 10-5 <4.78 10-4 <1.83  10-4 <1.37 10-4 <2.35 10-4 <4.21 10-5 
Sediment <1.54 10-6 <1.54 10-6 <1.54 10-6 <1.54 10-6 <1.54 10-6 <6.4510-7 
Sewage treatment 
plants 
0 0 0 0 0 - 
 
The EUSES program predicts that MDI will not induce perturbations to sewage treatment 
plants. This conclusion is obvious since releases of MDI by production and big processing 
plants (> 76% of tonnage) to STP are virtually non-existent. Moreover, any traces of MDI 
rejected into the water would undergo hydrolysis and disappear from effluent water very 
rapidly.  
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The atmospheric compartment was not included in the quantitative risk assessment because 
of the lack of information relevant to this compartment 
Secondary poisoning is very unlikely to occur considering the physico-chemical 
characteristics of MDI, assumption which is confirmed by the results of accumulation studies 
with MDI. 
Possible hazard due to MDA formation when MDI enters the water compartment was also 
assessed through calculation of local MDA PECs associated with MDI hydrolysis on the basis 
of a 2% yield. PECs estimated through this approach were negligible compared to the local 
PECs stated in the MDA risk assessment report (local MDA PECs from MDI: 2.8 10-8 
compared to 69 10-3 for MDA generic approach and 0.4 10–3 for MDA site-specific 
approach).  
It can thus be concluded that MDA amounts yielded by the hydrolysis of MDI will not lead to 
environmental hazards for aquatic organisms and will not influence the hazard due to 
production and use of MDA. 
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4 HUMAN HEALTH 
4.1 HUMAN HEALTH (TOXICITY) 
4.1.1 Exposure assessment 
Occupational exposure 
Occupational exposure may occur by inhalation of vapours and aerosols or through skin 
exposure at workplaces where MDI is produced or used.  Inhalation can theoretically also 
occur with dust arising from the handling of pure crystals of MDI.   
For the occupational exposure assessment the exposure situations can be clustered into 2 
scenarios: 
Scenario 1: Production of MDI and prepolymers in almost completely closed systems 
Scenario 2: Use of MDI as an intermediate by the downstream users.  This scenario considers 
the use of almost completely closed systems but also the use of MDI as an aerosol in spraying 
applications. 
An overview of the conclusions of the occupational exposure assessment is given in Table 
4.1. 
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Table 4. 1    Summary on the occupational exposure assessment 
Estimated inhalation exposure level (mg/m³) Exposure 
Full shift (8 hour time weighed average) Short-term 
Estimated skin 
exposure 
Scenario 
Duration (h/day) Frequency 
(day/year) 
Typical Method Reasonable 
Worst Case 
Method Level Method mg/day mg/kg.d
ay 
1 Chemical industry: 
 
MDI production 
 
Prepolymer production 
 
Continuous 
(8-hour-shifts) and 
batch-synthesis 
continuous 0.007 Meas.1 0.053 
1 
Meas.2 
EASE 
0.1 Expert 650 9.29 
2 Industrial and skilled trade sectors: 
 
Breached closed systems, partially open 
and manual processes 
 
Spraying 
 
Specialist contractor foam applicators 
 
 
   
 
Not 
estimated 
  
 
0.05 
1 
 
>10,000 
 
0.40 
 
 
Meas.2 
EASE 
 
EASE 
 
literature 
 
 
0.1 
 
 
 
 
0.57 
 
 
Expert 
 
 
 
 
literature 
 
 
1,300 
 
 
3,500 
 
3,500 
 
 
18.57 
 
 
50 
 
50 
 
Meas.1: data taken from industry measurements; median value 
Meas.2: data taken from industry measurements; 95 percentile 
EASE: calculated with the EASE model 
Expert: expert judgement; short-term exposure estimate = 2x Reasonable Worst Case 
Literature: data found in the literature 
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Consumer exposure 
Four scenarios are considered for consumer exposure: 
Scenario 1: Spray painting (liquid roof coating, outdoors) 
Scenario 2: Use of spray foam or One Component Foam (OCF) 
Scenario 3: Gluing, and the use of putty/filler in cartridge, painting with brush 
Scenario 4: Use of Hot Melt Adhesives 
The frequency of exposure is expected to be low i.e. to occur occasionally for short-term 
events.   
The main results of the consumer exposure assessment which are used in the risk 
characterisation are gathered in Table 4.2.   
Table 4. 2    External acute exposure for consumers 
  Acute Exposure Levels (External) 
Dermal      Scenario free MDI 
(%) 
Inhalation          (mg/m³) 
(mg/d) (mg/kg bw) 
(1)   Spray painting 0.1 - 5.35 0.076 
(2)   Use of OCF 10 0.0061 535 7.6 
(3)   Gluing, putty/filler 
cartridge, brush painting 
35 - 2,940 42 
(4)   Hot melt adhesives 2 0.025 168 2.4 
Humans exposed via the environment 
The EUSES model has been used to calculate the MDI human daily dose through food, air, 
and drinking water.  The main results are gathered in Table 4.3. Daily doses linked with 
releases in the local environment are expressed as a range of intake when considering all use 
patterns of MDI.  
Table 4. 3    Estimated human daily intake of MDI via the environment 
 Regional Local 
Daily dose through air (mg/kg.d) 4.41 10-8 1.74 10-7 – 5.04 10-6 
Daily dose through drinking water (mg/kg.d) 1.95 10-8 1.95 10-8 – 1.41 10-7  
Daily dose through fish (mg/kg.d) 2.99 10-6 2.99 10-6 
Daily dose through leaf crop (mg/kg.d) 8.78 10-8 3.47 10-7 – 1 10-5 
Daily dose through root crop (mg/kg.d) 6.35 10-7 8.11 10-7 – 7.31 10-6 
Daily dose through meat (mg/kg.d) 1.46 10-9 5.23 10-9 – 1.47 10-7 
Daily dose through milk (mg/kg.d) 8.62 10-10 3.09 10-9 – 8.66 10-8 
Total daily intake for humans (mg/kg.d) 3.78 10-6 4. 35 10-6 – 2.57 10-5 
 
At the regional level, intake from fish is the most important source of MDI; on the local scale, 
man is mainly exposed via fish and vegetable consumption and via the air.   
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However, given the reactivity with water and the information available on the absence of 
accumulation of MDI in organisms, it is very unlikely that MDI becomes available in the food 
chain.   
Combined exposure 
On the basis of the exposure estimates given, humans can be exposed to MDI as a result of 
combined exposure.  However, indirect exposure via the environment can be considered to be 
negligible for the calculation of the combined exposure.   
As a reasonable worst-case (RWC), someone who works in the industrial and skilled trade 
sector, and is exposed at home doing some ‘D.I.Y3.’ (e.g. use of OCF4) will receive a 
maximum dose of MDI which can be quantified as is shown in Table 4.4. 
Table 4. 4     Calculated combined exposure  
Exposure pathway Acute exposure Lifetime exposure1 
Inhalative Workplace2 
WC 0.05 mg/m³ 
 
Consumer3 
WC 0.0061 mg/m³ 
Workplace2 
WC 68.57 mg/kg bw 
 
Consumer3 
WC 0.14 mg/kg bw 
Dermal Workplace4 
WC exposure 1,300 mg/d, 
WC uptake 13 mg/d 
 
Consumer5 
WC exposure 535 mg/d 
WC uptake 5.35 mg/d 
Workplace4 
WC exposure 178.3 g/kg bw, 
WC uptake 1,783 mg/kg bw  
 
Consumer5 
WC exposure 1.2 g/kg bw, 
WC uptake 12 mg/kg bw 
 
1 for the calculation of lifetime doses following parameters were used: 70 kg bw (adult), 1.25 m³/h inhaled air for a consumer 
doing D.I.Y.-jobs for working 8h/d, 4 days/y for 40 years (consumer), 10 m³/8 h workshift inhaled air, 5 days/week 48 
weeks/y and 40 years working period (worker), dermal absorption 1%.   
 
2 worst case inhalation exposure for the occupational scenarios 1 and 2 is 0.05 mg/m³.   
3 worst case inhalation exposure for consumer scenario 2 (use of OCF) is 0.0061 mg/m³.   
4 worst case dermal exposure for almost all applications in the occupational scenario 2 (industrial and skilled trade sector) is 
1300 mg/d.   
5 worst case dermal exposure for consumer scenario 2 (use of OCF) is 535 mg/d.   
4.1.2 Effects assessment 
Toxicokinetics, metabolism and distribution 
There are few data available on the toxicokinetics and fate of MDI in humans.  Urinary 4,4’-
methylenedianiline, measured after acid hydrolysis, has been suggested as a biomarker for the 
short-term exposure to MDI.  4,4’-methylenedianiline (4,4’-MDA), released by hydrolysis of 
plasma or haemoglobin, has been suggested as a biomarker of intermediate and long-term 
                                                 
3 Do it yourself 
4 One component foam 
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exposure to MDI.  No information is available on the toxicokinetics of MDI following oral 
exposure in animals.   
Contradictory results have been obtained with respect to dermal exposure.  Eventually, as 
reasonable worst-case estimate, a dermal absorption of 1% was taken forward to the risk 
characterisation. 
With respect to inhalation exposure, there is reliable data regarding distribution/excretion in 
experimental animals.  In biomonitoring studies haemoglobin adducts and urine metabolites 
of MDI were determined.  From the data generated to date, it is not possible to state 
categorically that the MDA measured in the majority of studies investigating levels in blood 
and plasma represents a metabolite of MDI.  The results of the inhalation 
metabolism/toxicokinetics/distribution study indicate that a proportion of the MDI dose is 
converted to metabolites via the intermediary formation of an amine group which is rapidly 
acetylated.  However, the current data do not allow entire elucidation of the mechanisms 
involved in the biological transport and transformation of MDI.  Further studies using 
biologically relevant in vitro systems are ongoing.  Additional studies are being designed to 
investigate metabolism of formed conjugates and any role of free or bound MDA in MDI 
formation.   
Acute toxicity 
Assessment of the available acute toxicity data indicates that inhalation exposure to respirable 
aerosols of MDI results in toxicity confined predominantly to the respiratory tract.  A well-
conducted animal study gives a LC50 (4 h, rat) of 490 mg/m³.  The limited data available from 
animal studies indicate that MDI is of low oral and dermal acute toxicity, with an oral LD50 
(rat) > 10,000 mg/kg bw and dermal LD50 (rabbit) > 10,000 mg/kg bw.   
Irritation 
MDI is a known skin and eye irritant.  The toxicity studies, mechanistic studies, and human 
data indicate that MDI causes irritation of the respiratory tract.  A RD50 (mice), due to 
pulmonary irritation, of 32 mg/m³ was found.  An acute irritant threshold concentration of 0.5 
mg/m³ was estimated from rat studies based on the most sensitive (and reversible) endpoints 
in bronchoalveolar lavage fluid. 
Sensitisation 
MDI has also a skin sensitising potential.  Animal studies indicate that MDI is a strong 
allergen.  A few human case reports describe allergic contact dermatitis due to MDI exposure.  
MDI is a well-established respiratory sensitiser in animals and humans.  Animal studies have 
shown that respiratory sensitisation can be induced by skin contact with MDI.  The 
quantitative relationships between exposure (concentration, duration, rate of exposure, route 
of exposure) and incidence of sensitisation have not been established.  No threshold level for 
sensitisation could be determined.  Extensive information is available on the mechanism of 
hypersensitivity.  Cross-reactivity with other isocyanates has been described in several 
publications.   
Repeated dose toxicity 
No results from repeated-dose toxicity tests are available for the oral and dermal route of 
exposure.   
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Well-conducted short-term and long-term inhalation animal studies indicate the respiratory 
tract to be the target organ of respirable MDI aerosol.   
The most reliable NOAEL of short-term toxicity is 1.4 mg/m³; LOAEL being 2 mg/m³ (based 
on increased lung weights). However, mechanistic studies revealed a LOEL of 1.1 mg/m³ 
(based on changes in the phospholipid content of alveolar macrophages and non-specific cell 
proliferation of Type II pneumocytes).  These findings are consistent with the sub-acute 
LOAEL of 1 mg/m³ found for effects on the surfactant homeostasis. In an acute rat inhalation 
study a LOAEL of 0.7 mg/m³ was found for transient dysfunction of the pulmonary epithelial 
barrier (NOAEL being estimated at 0.5 mg/m³). For the risk characterisation, the NOAEL = 
0.5 mg/m³ is used for acute irritation after short-term inhalation (consumers). 
The reported NOAELs for chronic toxicity (inhalation, rat, 2 years) are 0.23 mg/m³ and 0.2 
mg/m³; LOAEL being 1 mg/m³.  For the risk characterisation, the most reliable NOAEL = 0.2 
mg/m³ is used for inflammatory and other non-neoplastic pulmonary changes after long-term 
inhalation exposure (workers). 
The effect of long-term exposure of MDI on the respiratory system of humans has been 
described in several studies.  Long-term exposure of MDI tends to cause restriction of 
pulmonary function and decline on pulmonary diffusing capacity.  In addition to reports of 
cases of asthma, hypersensitivity pneumonitis, pleuritis, and progressive fibrosing alveolitis it 
may be concluded that chronic exposure to even low levels (mostly undetermined or below 
0.05 mg/m³) of MDI carries a risk of respiratory disease.  
Mutagenicity 
From the body of available data it is concluded that MDI does not have genotoxic properties.  
Conflicting results were obtained in in vitro test systems.  The results from the requested in 
vivo micronucleus test indicate that aerosolized, inhaled MDI at concentrations as high as 118 
mg/m³ air (a concentration high enough to produce portal-of-entry-specific toxic effects, 
including statistically significantly increased lung weights) did not induce cytogenetic damage 
in vivo.   
Carcinogenicity 
In a well-conducted chronic toxicity/carcinogenicity animal inhalation study, tumours in the 
lungs were found, without adverse effect on the distribution and incidence of tumours apart 
from these lung tumours.  In another long-term animal inhalation study a single bronchio-
alveolar adenoma was found at 2.05 mg/m³ MDI.  There are two hypotheses concerning the 
oncogenesis of MDI: 1° oncogenesis on the basis of irritation through epigenetic mechanisms, 
2° oncogenesis resulting from the formation of MDA (4,4’-methylenedianiline).  A NOAEL 
of 0.2 mg/m³ is established for inflammatory and other non-neoplastic pulmonary changes.  
No carcinogenicity studies are available using the oral or dermal route of exposure.  There is 
inadequate evidence of carcinogenicity in humans and limited evidence in experimental 
animals.   
Toxicity for reproduction 
No fertility or multigeneration studies are available for MDI.  Data from (sub)chronic toxicity 
studies did not reveal clear substance related and/or significant impairment of organs of the 
reproductive system of the male and female.  Taken together, these studies were considered 
too limited to allow a determination of a NOAEL for fertility.  Pre-natal inhalation toxicity 
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testing in rats indicated the absence of selective toxicity to the development (no findings 
indicated any specific developmental effects at exposure levels below those that caused 
maternal toxicity).  The reported NOAEL(developmental) for monomeric MDI is 3 
mg/m³/day and the NOAEL(developmental) for polymeric MDI is 4 mg/m³/day.  No data on 
reprotoxicity are available in humans. 
4.1.3 Risk characterisation 
Workers 
The risk characterisation for workers is limited to the dermal and respiratory routes of 
exposure.  Because it its generally known that MDI is a harmful, irritating, and sensitising 
agent, high inhalation and dermal exposure levels are avoided in practice and the use of 
protective measures have been taken into account on the exposure estimates. 
Table 4.5 provides an overview of the conclusions reached in the risk characterisation for 
workers for different exposure scenarios and different toxicological endpoints.  
Table 4. 5    Overview of conclusions with respect to occupational risk characterisation 
End point  
and outcome of the key study used  
Conclusions valid for the occupational scenarios 
 
in risk characterisation (between brackets) Scenario 1: Chemical Industry 
 
Scenario 2: Downstream users 
 MOS 
 
Conclusion MOS  Conclusion  
Acute toxicity 
- oral (LD50 rat >10,000 mg/kg bw) 
- dermal (LD50 rabbit >10,000 mg/kg bw) 
 
- inhalation (LC50, 4h, rat: 490 mg/m3) 
 
 
- 
1,076 
 
4,900 
 
ii 
ii 
 
ii 
 
- 
-539 (200 for  
specialist 
contractor 
foam 
applicators) 
4,900 (860 for 
specialist 
contractor 
foam 
applicators) 
 
ii 
ii 
 
ii 
Irritation 
dermal (irritant) 
 
eyes (irritant) 
 
 
 
respiratory tract 
 
 
- 
 
 
- 
 
 
9.4 
 
ii 
 
 
ii 
 
 
iii 
 
- 
 
 
- 
 
 
10 
1.3 (specialist 
contractor 
 
ii (exception: 
unprotected workers 
on building sites: iii) 
ii (exception: 
unprotected workers 
on building sites: iii) 
iii 
iii 
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End point  
and outcome of the key study used  
Conclusions valid for the occupational scenarios 
 
in risk characterisation (between brackets) Scenario 1: Chemical Industry 
 
Scenario 2: Downstream users 
 MOS 
 
Conclusion MOS  Conclusion  
foam 
applicators) 
Sensitisation 
- dermal (sensitising) 
- inhalation (sensitizing) 
 
- 
- 
 
iii 
iii 
 
- 
- 
 
iii 
iii 
 
Repeated dose toxicity, systemic effects, including 
possible carcinogenicity 
- dermal (no studies) 
- inhalation  (NOAEL rat, 0.2mg/m3) 
- combined 
 
 
 
- 
3.77 
0.6 
 
 
 
ii 
iii 
iii 
 
 
 
- 
4 
0.3 
0.1 (specialist 
contractor 
foam 
applicators) 
 
 
 
ii 
iii 
iii 
iii 
Mutagenicity (no evidence for mutagenicity) 
 
- ii - ii 
Reproductive toxicity 
- inhalation 
Fertility (database not adequately enough) 
 
Developmental toxicity (NOAELdev, rat, 3 mg/m³/d) 
 
 
 
- 
 
57 
 
 
i on hold 
 
ii 
 
 
- 
 
60 
7.5 (specialist 
contractor 
foam 
applicators), 
but PPE 
 
 
i on hold 
 
ii 
ii 
Consumers 
Table 4.6 provides an overview of the conclusions reached in the risk characterisation for 
consumers for different exposure scenarios and different toxicological endpoints. Scenario 1: 
Spray painting; Scenario 2: Use of spray foam ‘OCF’; Scenario 3: Gluing, putty/filler 
adhesives, painting with brush/roller; Scenario 4: Hot melt adhesives. 
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Table 4. 6    Overview of conclusions with respect to consumer characterisation 
Endpoint Conclusions valid for the consumer scenarios 
 Scenario 1 Scenario 2 Scenario 3 Scenario 4 
Acute toxicity (oral, dermal, inhalation) 
Irritation (skin, eyes) 
Irritation (respiratory tract) 
Sensitisation (dermal, inhalation) 
Lung effects induced by short-term 
repeated exposure 
Chronic toxicity / carcinogenicity 
Mutagenicity 
Reproductive toxicity (fertility) 
Reproductive toxicity (developmental) 
Physicochemical properties 
ii 
iii 
ii 
iii 
ii 
 
ii 
ii 
i on hold 
ii 
ii 
ii 
iii 
iii 
iii 
iii 
 
ii 
ii 
i on hold 
ii 
ii 
ii 
iii 
ii 
iii 
ii 
 
ii 
ii 
i on hold 
ii 
ii 
ii 
iii 
iii 
iii 
iii 
 
ii 
ii 
i on hold 
ii 
ii 
 
Humans exposed via the environment 
The human exposure from the indirect exposure in local and regional scenarios is presented in 
Table 4.7.  The estimations were performed according to EUSES.   
Table 4. 7    Estimated human exposure via the environment and MOS5 
 MOS Total MOS Air 
Local scale:   
Production 1.32 104 3.28 105 
Processing to polyurethanes 2.24 103 1.13 104 
Processing of prepolymers – 
speciality MDI’S 
6.75 103 5.05 104 
Processing of prepolymers – other 
than speciality MDI’S 
4.27 103 2.54 104 
Processing to prepolymers 5.33 103 3.46 104 
Regional scale 1.52 104 1.30 106 
 
Given that exposure levels are most probably much lower than calculated by the model on 
account of the very high reactivity of MDI with water and the worst case assumptions upon 
which the calculations were based, and in view of the MOS obtained (minimum 2,240), it can 
be concluded that exposure of humans to MDI through the environment is not expected to 
lead to any health hazard: Conclusion (ii). 
                                                 
5 Margin of safety  
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Combined exposure 
Combining occupational, consumer and indirectly via the environment exposure will not 
materially influence the characterisation of the risks associated with occupational exposure 
alone. 
4.2 HUMAN HEALTH (PHYSICO-CHEMICAL PROPERTIES) 
With regard to the physico-chemical properties and with regard to the occupational, 
consumer, indirect and combined exposure, MDI is not expected to cause specific concern 
relevant to human health.   
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5 RESULTS 
5.1 ENVIRONMENT 
Conclusion (ii) There is at present no need for further information and/or testing and no need for 
risk reduction measures beyond those which are being applied already. 
The risk assessment shows that risks are not expected  
5.2 HUMAN HEALTH (TOXICITY) 
Workers 
Conclusion (i) There is a need for further information and/or testing. 
Conclusion (iii) There is a need for limiting the risks; risk reduction measures which are already 
being applied shall be taken into account. 
Conclusion (i) on hold applies to the current database which does not adequately cover the toxicity for 
fertility.  The collection of additional better information to adequately characterise the risks regarding 
this endpoint should, however, not delay the implementation of appropriate control measures needed to 
address the concerns related to other endpoints. 
Conclusion (iii) applies to  
• skin and eye irritation for workers on building sites, as in this case occupational hygiene 
standards are often low and PPE might not be worn. 
• respiratory tract irritation as a consequence of inhalation exposure arising from all 
investigated occupational exposure scenarios. 
• skin and respiratory sensitisation as a consequence of dermal and inhalation exposures 
arising from all investigated occupational exposure scenarios. 
• respiratory toxicity as a consequence of repeated inhalation exposure arising from all 
investigated occupational exposure scenarios. 
Consumers 
Conclusion (i) There is a need for further information and/or testing. 
Conclusion (iii) There is a need for limiting the risks; risk reduction measures which are already 
being applied shall be taken into account. 
Conclusion (i) on hold applies to the current database which does not adequately cover the toxicity for 
fertility.  The collection of additional better information to adequately characterise the risks regarding 
this endpoint should, however, not delay the implementation of appropriate control measures needed to 
address the concerns related to other endpoints. 
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Conclusion (iii) applies to  
• skin and eye irritation as a consequence of exposure arising from the use of all types of 
MDI-containing consumer products. 
• respiratory tract irritation as a consequence of inhalation exposure arising from the use 
of MDI-containing one component foams (OCFs) and hot melt adhesives. 
• skin and respiratory sensitisation as a consequence of dermal and inhalation exposures 
arising from the use of all types of MDI-containing consumer products. 
• lung effects as a consequence of inhalation by short-term repeated exposure arising 
from the use of MDI-containing one component foams (OCFs) and hot melt adhesives. 
Humans exposed via the environment 
Conclusion (ii) There is at present no need for further information and/or testing and no need for 
risk reduction measures beyond those which are being applied already. 
The risk assessment shows that risks are not expected. Risk reduction measures already being applied 
are considered sufficient. 
Combined exposure 
Conclusion (i) There is a need for further information and/or testing. 
Conclusion (iii) There is a need for limiting the risks; risk reduction measures which are already 
being applied shall be taken into account. 
Conclusion (i) on hold applies to the current database which does not adequately cover the toxicity for 
fertility.  The collection of additional better information to adequately characterise the risks regarding 
this endpoint should, however, not delay the implementation of appropriate control measures needed to 
address the concerns related to other endpoints. 
Conclusion (iii) applies to  
• eye, skin, respiratory tract irritation as a consequence of  exposure arising from 
combined occupational and consumer exposure. 
• skin and respiratory sensitisation as a consequence of dermal and inhalation exposures 
arising from combined occupational and consumer exposure. 
• respiratory toxicity as a consequence of repeated inhalation exposure arising from 
combined occupational and consumer exposure. 
5.3 HUMAN HEALTH (RISKS FROM PHYSICO-CHEMICAL PROPERTIES) 
Conclusion (ii) There is at present no need for further information and/or testing and no need for 
risk reduction measures beyond those which are being applied already. 
The risk assessment shows that no concern is expected related to the physico-chemical properties of 
MDI. Risk reduction measures already being applied are considered  sufficient. 
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Abstract 
 
The report provides the comprehensive risk assessment of the substance Methylenediphenyl diisocyanate 
(MDI). It has been prepared by Belgium in the frame of Council Regulation (EEC) No. 793/93 on the evaluation 
and control of the risks of existing substances, following the principles for assessment of the risks to humans 
and the environment, laid down in Commission Regulation (EC) No. 1488/94. 
 
Part I - Environment 
This part of the evaluation considers the emissions and the resulting exposure to the environment in all life cycle 
steps. Following the exposure assessment, the environmental risk characterisation for each protection goal in 
the aquatic, terrestrial and atmospheric compartment has been determined. The environmental risk assessment 
concludes that there is no concern. 
 
Part II – Human Health 
This part of the evaluation considers the emissions and the resulting exposure to human populations in all life 
cycle steps. The scenarios for occupational exposure, consumer exposure and humans exposed via the 
environment have been examined and the possible risks have been identified. The human health risk 
assessment concludes that there is concern for workers and consumers with regard to irritation of skin, eye and 
respiratory tract, skin sensitisation and lung effects induced by repeated inhalation exposure. There is a need 
for further information and for testing (on hold) on the toxicity for fertility for workers and consumers. For 
humans exposed via the environment and for human health (physico-chemical properties) there is no concern. 
The conclusions of this report will lead to risk reduction measures to be proposed by the Commission’s 
committee on risk reduction strategies set up in support of Council Regulation (EEC) N. 793/93. 
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